Patent details
300507
Product Name:
Telavancine, of een farmaceutisch aanvaardbaar zout daarvan, inclusief telavancine hydrocloride.
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300507
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1292612
Status:
Invalid because the basic patent has lapsed before the expiration date or has been revoked
Application number:
300507
Procedural language:
Dutch
First Applicant Residence Country:
Marketing Authorization
Marketing Authorization Number:
EU/1/11/705/001 - 002
Marketing Authorization Type:
EEA
Marketing Authorization Date:
02/09/2011
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
05/12/2011
First Marketing Authorization date:
02/09/2011
Grant date:
12/01/2012
Activation date:
01/05/2021
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
05/12/2011
SPC/SPC Extension Expiration Date:
30/04/2026
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
10/11/2015
Name:
Theravance Biopharma Antibiotics IP, LLC.
Address:
901 Gateway Boulevard, 94080, South San Francisco, California, United States of America (US)
Historical Applicant/holder
From:
10/11/2015
To:
10/11/2015
Name:
Theravance, Inc.
Address:
951 Gateway Boulevard, 94080, South San Francisco, California, United States of America (US)
Agent
Name:
ir. J.C. Volmer c.s.
From:
05/12/2011
Address:
Exter Polak & Charlouis B.V.
Postbus 3241, 2280 GE, Rijswijk, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
02/20
Publication date:
13/01/2020
Description:
Lapse or annulment
2
Bulletin Heading:
CO
Journal edition number:
12/16
Publication date:
23/03/2016
Description:
Changes in the Netherlands Patent Register
3
Bulletin Heading:
SPC
Journal edition number:
2012/04
Publication date:
25/01/2012
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
4
Bulletin Heading:
SPC
Journal edition number:
2011/50
Publication date:
14/12/2011
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Deed
Change of Address
Change Kind/ Decision Type:
Owner
Deed Number:
RC201600362A
Date Registered:
10/11/2015
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. J.C. Volmer c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Change of owner(s)
Change Kind/ Decision Type:
Assignment
Deed Number:
RC201600362B
Date Registered:
10/11/2015
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. J.C. Volmer c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Added Owner(s)
Name:
Theravance Biopharma Antibiotics IP, LLC.
Address:
901 Gateway Boulevard, 94080, South San Francisco, California, United States of America (US)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Annual Fee
Annual Fee(s) Due Date:
30/04/2021
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date
Document type
Document Description
Number of pages
File Type
12/01/2012
SPC Documents
Certificate SPC
1
PDF
/7/0/5/0/0/0400300507/docs/300507_4_supplprotectioncertificate20200909050409832.pdf
12/01/2012
Outgoing Correspondence
Outgoing Letter
2
PDF
/7/0/5/0/0/0400300507/docs/300507_9_outgoingcorrespondence20120112.pdf
17/12/2011
Application Form
First filed application form
2
PDF
/7/0/5/0/0/0400300507/docs/300507_7_applicationform20111205.pdf
06/12/2011
Outgoing Correspondence
Outgoing Letter
1
PDF
/7/0/5/0/0/0400300507/docs/300507_8_outgoingcorrespondence20111206.pdf
05/12/2011
SPC Documents
Annex SPC
3
PDF
/7/0/5/0/0/0400300507/docs/300507_0_supplprotectioncertificate20200909051229641.pdf
05/12/2011
SPC Documents
Marketing Authorization SPC
4
PDF
/7/0/5/0/0/0400300507/docs/300507_1_supplprotectioncertificate20200909050002670.pdf
05/12/2011
SPC Documents
Annex SPC
3
PDF
/7/0/5/0/0/0400300507/docs/300507_2_supplprotectioncertificate20200909045556785.pdf
05/12/2011
SPC Documents
Annex SPC
17
PDF
/7/0/5/0/0/0400300507/docs/300507_3_supplprotectioncertificate20200909045556683.pdf
05/12/2011
SPC Documents
Accompanying letter SPC
1
PDF
/7/0/5/0/0/0400300507/docs/300507_5_supplprotectioncertificate20200909050145400.pdf
05/12/2011
SPC Documents
Summary of the characteristics of the product
27
PDF
/7/0/5/0/0/0400300507/docs/300507_6_supplprotectioncertificate20200909045556611.pdf